| Document |
Document Title |
|
WO/2024/102977A1 |
Disclosed herein are genetically engineered cells for AAV production. The genetically engineered cell comprises molecular systems for temporal control of expression of genes required for AAV production. Also disclosed herein are methods ...
|
|
WO/2024/099975A1 |
The invention relates to nanoparticles for Cas protein/gRNA ribonucleoprotein (RNP) complex, siRNA or PMO delivery comprising one or more Cas protein/gRNA RNP complex(es), siRNA(s) or PMO(s) as cargo; and a carrier comprising a sequence-...
|
|
WO/2024/102972A1 |
Provided herein are compositions for gene modification related to base editor systems, and methods of using the same to treat or prevent conditions associated with the extracellular deposition in various tissues of amyloid fibrils formed...
|
|
WO/2024/072224A3 |
The present invention relates to a peptide-based compound for complexing and stabilizing a double stranded oligonucleotide, the compound comprising a structure p-x-b-x'-p'; wherein: i. p and p' each refer to an oligonucleotide-binding mo...
|
|
WO/2024/102943A1 |
Described herein are immunoresponsive cells engineered to express cytokines, chimeric receptors, and synthetic transcription factor systems. Also described herein are nucleic acids, cells, and methods directed to the same.
|
|
WO/2024/098383A1 |
Disclosed are a protein mutant with a sequence having more than 80% identity to SEQ ID NO. 1, a gRNA used in combination with the protein mutant, a gene editing system, an expression vector, a modified cell, a pharmaceutical composition,...
|
|
WO/2024/102764A1 |
The disclosure relates to methods of treating cancer in a subject administering nucleic acid molecules comprising a nucleic acid sequence encoding a plurality of neoantigens. Vaccines, compositions comprising coding regions encoding neoa...
|
|
WO/2024/098939A1 |
Provided is a bifunctional fusion protein, comprising a first domain specifically recognizing interleukin-6 receptor (IL-6R), and a second domain specifically binding to cell surface protein CD47. Also provided is a method of using said ...
|
|
WO/2024/099320A1 |
A hybrid protein containing a CFH functional unit and a DAF functional unit, and a mutant thereof, an encoding nucleic acid thereof, and a method and the use thereof for treating diseases or conditions related to a complement system; and...
|
|
WO/2024/101433A1 |
A glycosylated neuropeptide derivative comprising a neuropeptide sequence, a membrane-penetration-promoting sequence, an endosomal-escape-promoting sequence, and a sugar chain.
|
|
WO/2024/102436A1 |
Provided herein is an engineered controllable membrane targeting system based on triggered exposure of a cryptic acylation signal, a calcium-regulated protease that can be used to expose this cryptic acylation signal, a means of coupling...
|
|
WO/2024/100557A1 |
Provided are glycoprotein NMB (GPNMB)-binding chimeric antigen receptors (CARs). In some embodiments, a CAR of the present disclosure comprises an extracellular GPNMB-binding domain (e.g., a single chain antibody, such as an scFv), a tra...
|
|
WO/2024/101434A1 |
This physiologically-active peptide derivative for the treatment of eye diseases comprises a physiologically-active peptide sequence and a functional sequence comprising a membrane permeation-promoting sequence and an endosomal escape-pr...
|
|
WO/2024/103049A1 |
Disclosed are exosomes comprising an extracellular CD33 binding motif fused to a transmembrane protein. Disclosed are methods of making a cell derived exosome comprising: transfecting a plasmid into cells, wherein the plasmid comprises a...
|
|
WO/2024/102954A1 |
Disclosed are nucleic acids encoding fusion proteins containing a target binding domain, a cleavage domain cleavable by A Disintegrin and Metalloproteinase (ADAM) 17, and a transmembrane domain.
|
|
WO/2024/097877A1 |
Provided herein are ZP4 antibodies and ZP4-specific chimeric antigen receptors (CARs). Further provided herein are immune cells expressing the ZP4-specific CARs and methods of treating cancer by administering the ZP4-specific CAR immune ...
|
|
WO/2024/094159A1 |
Provided in the present application are a single domain antibody targeting the ROR1 protein as well as a chimeric antigen receptor (CAR) and CAR-T cell comprising the single domain antibody. Also provided are uses of the single domain an...
|
|
WO/2024/093147A1 |
The present invention relates to an antibody specifically binding to the v5 exon of human CD44 or a fragment thereof. The present invention also relates to a chimeric antigen receptor molecule comprising the antibody or the fragment ther...
|
|
WO/2024/094002A1 |
The present invention relates to a fructose diphosphate optical probe. Specifically, provided in the present invention is a fructose diphosphate optical probe, which comprises a fructose-1,6-diphosphate sensitive polypeptide and an optic...
|
|
WO/2024/092769A1 |
Provided is a fusion polypeptide comprising a carrier protein and a polypeptide of interest, wherein the polypeptide of interest is fused to a terminus of the carrier protein or inserted into the carrier protein, and wherein the carrier ...
|
|
WO/2024/097938A1 |
The present disclosure generally relates to compositions and methods for enhancing transportof molecules into the brain using modified IgG Fc regions, and methods of producing and using molecules comprising such modified Fc regions.
|
|
WO/2024/094224A2 |
Provided in the present invention are a PBase protein, a fusion protein, a nucleic acid, a gene integration system, a gene delivery system and the use. The PBase protein retains the abilities of binding to the ITR sequences of a Piggybac...
|
|
WO/2024/094004A1 |
The invention belongs to the technical field of cell immune engineering, and particularly relates to a fully human antigen binding fragment and single chain fragment variable targeting CD123, and a use thereof. The single chain fragment ...
|
|
WO/2024/093882A1 |
Provided are a group CD24 binding proteins and uses thereof. Specifically provided is a group of antigen binding proteins, wherein cells expressing the antigen binding protein can have cytotoxicity and safety. Also provided is a use of t...
|
|
WO/2024/093056A1 |
The present invention relates to a T cell receptor (TCR) specifically binding to a KRAS_G12V mutant antigen, a fusion protein or conjugate comprising the TCR, a nucleic acid encoding the TCR and an engineered cell comprising same, and a ...
|
|
WO/2024/093554A1 |
The present invention relates to the field of biomedicine, in particular to a recombinant subunit vaccine against respiratory syncytial virus (RSV) and a use thereof, and more in particular to a recombinant fusion protein containing the ...
|
|
WO/2024/097797A1 |
T cells expressing a chimeric antigen receptor (CAR) targeting CD3 can be susceptible to fratricide because T cells express CD3 on their surface as part of the T cell receptor (TCR)/CD3 complex. To reduce fratricide, CD3 surface expressi...
|
|
WO/2024/094527A1 |
The invention relates to novel means to produce protein multimers that are multimerised in vivo using self-associating multimerisation domains (SAMs), such as self-associating tri- or tetramerisation domains.
|
|
WO/2024/097992A2 |
Provided herein are particles comprising a fusion molecule comprising an adhesion molecule linked to a costimulatory molecule or an activation molecule, as well as vectors, such as lentiviral vectors, comprising the same, cells comprisin...
|
|
WO/2024/094076A1 |
Provided are a GIPR binding protein and a use thereof. Specifically provided are a single-domain antibody specifically binding to a glucose-dependent insulinotropic polypeptide receptor, a derived protein thereof, and a pharmaceutical use.
|
|
WO/2024/097875A1 |
The present disclosure relates to, inter alia, compositions and methods, including heterologous chimeric proteins that find use, inter alia, in the treatment of nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NAS...
|
|
WO/2024/092001A1 |
The present disclosure provides methods for preventing or treating Alzheimer's disease in a subject, and/or reducing the likelihood or severity of Alzheimer's disease comprising administering to the subject an effective amount of an anti...
|
|
WO/2024/091775A1 |
Provided are variant Cas12f4 polypeptides, fusion proteins containing variant Cas12f4 polypeptides, nucleic acids encoding variant Cas12f4 polypeptides and fusion proteins, compositions and methods related to those variant Cas12f4 polype...
|
|
WO/2024/087761A1 |
The present invention relates to a method for producing a polypeptide from a recombinant fusion protein, and disclosed are a method for producing a polypeptide by means of serially combining multiple protease cleavage sites and polypepti...
|
|
WO/2024/088325A1 |
The present invention relates to an antibody that specifically binds to CLDN6, and the use thereof.
|
|
WO/2024/092095A1 |
Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of a vascular disease, such as coronary artery disease (CAD), in a subject. In particular, provided are methods and compositions for treating a vasc...
|
|
WO/2024/088371A1 |
An isolated antigen-binding protein capable of targeting MSLN. The isolated antigen-binding protein comprises at least one CDR in an antibody heavy chain variable region VH, and the VH comprises an amino acid sequence represented by any ...
|
|
WO/2024/091889A1 |
Flt3L is a soluble, focused signal that can expand the dendritic cell compartment. The disclosure provides for methods for regenerating tissue, for preventing wound formation, or for treating wounds in a subject. The methods are achieved...
|
|
WO/2024/088404A1 |
This disclosure provides engineered 4-1BBL variants, and methods of use thereof.
|
|
WO/2024/087405A1 |
A Cas mutant protein. Compared with a parent Cas protein, the Cas mutant protein has a significantly improved editing activity and broad application prospects.
|
|
WO/2024/089671A1 |
The present invention discloses a fusion protein SEQ ID NO: 1, comprising dodecin and Flavin Binding Fluorescent Protein (FBFP) for sequestering riboflavin to prevent the formation of skunk beer. The invention discloses the process of co...
|
|
WO/2024/082681A1 |
Provided are a fusion protein, and a nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein. The present invention also relates to a vaccine comprising the fusion protein or the nucleic acid molecule. Furtherm...
|
|
WO/2024/085143A1 |
The purpose of the present invention is to provide a novel peptide that could be used to induce an immune response to SARS-CoV-2. A nucleocapsid-derived antigen peptide according to the present disclosure includes the following polypep...
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/083226A1 |
An activatable antibody fusion protein, said fusion protein comprising an antibody portion specifically binding to a target, an immunoglobulin Fc portion, a masking portion and a cytokine portion. The present invention further relates to...
|
|
WO/2024/084932A1 |
[Problem] To provide a new carrier peptide fragment having cell membrane permeability. [Solution] The carrier peptide fragment disclosed herein is introduced into at least the cytoplasm of a eukaryotic cell from outside the cell and comp...
|
|
WO/2024/082795A1 |
The present invention relates to a protein and a vaccine against infections of SARS-CoV-2 Omicron mutant strain XBB and a subtype thereof, which belong to the field of medicines. In order to solve the problem of lack of effective prevent...
|
|
WO/2024/082262A1 |
Provided are a splicing system for controlling virus replication in response to a hypoxic environment, and a use thereof. The system comprises, mutually separated or fused to one another, a gene encoding an hypoxia sensing unit and a gen...
|
|
WO/2024/083097A1 |
Disclosed in the present invention is an IL-2 mutant, having at least one of the following mutations on an amino acid sequence of IL-2: 1) an insertion of at least one amino acid residue having a smaller side chain between positions T10 ...
|
|
WO/2024/085280A1 |
The present invention relates to a novel kynureninase and a use thereof for cancer treatment. The novel kynureninase demonstrates similar or higher catalytic activity and thermal stability compared to already known kynureninases, and is ...
|
